New hope for HIV patients when standard drugs fail
NCT ID NCT03902522
Summary
This study tested an experimental drug called PRO 140 in combination with other HIV medications for people whose current treatments were no longer working well. It involved 6 adults with HIV who had developed resistance to multiple classes of standard drugs. Researchers measured whether adding PRO 140 could reduce virus levels and was safe over 25 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CD02_OpenLabel Investigational Site
Palm Springs, California, 92262, United States
-
CD02_OpenLabel Investigational Site
San Francisco, California, 94115, United States
-
CD02_OpenLabel Investigational Site
New Haven, Connecticut, 06510, United States
-
CD02_OpenLabel Investigational Site
Ft. Pierce, Florida, 34982, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33136, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33139, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33169, United States
-
CD02_OpenLabel Investigational Site
Orlando, Florida, 32803, United States
-
CD02_OpenLabel Investigational Site
West Palm Beach, Florida, 33401, United States
-
CD02_OpenLabel Investigational Site
Decatur, Georgia, 30033, United States
-
CD02_OpenLabel Investigational Site
Chicago, Illinois, 60613, United States
-
CD02_OpenLabel Investigational Site
Wichita, Kansas, 67214, United States
-
CD02_OpenLabel Investigational Site
Syracuse, New York, 13210, United States
-
CD02_OpenLabel Investigational Site
Bellaire, Texas, 77301, United States
-
CD02_OpenLabel Investigational Site
Houston, Texas, 77004, United States
-
CD02_OpenLabel Investigational Site
Houston, Texas, 77098, United States
-
CD02_OpenLabel Investigational Site
Spokane, Washington, 99202, United States
Conditions
Explore the condition pages connected to this study.